Chemomab Therapeutics Ltd DRC Total Liabilities
Chemomab Therapeutics Ltd DRC total liabilities. Based on the latest financial reports, Chemomab Therapeutics Ltd DRC (CMMB) has total liabilities worth $1.55 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Chemomab Therapeutics Ltd DRC (CMMB) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Chemomab Therapeutics Ltd DRC (2012–2025)
Total liabilities of Chemomab Therapeutics Ltd DRC from 2012 to 2025. This chart illustrates how Chemomab Therapeutics Ltd DRC's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Chemomab Therapeutics Ltd DRC to see how much of total assets are deployed in long-term investments.
Chemomab Therapeutics Ltd DRC Competitors by Total Liabilities
The table below lists competitors of Chemomab Therapeutics Ltd DRC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou Goldengreen Technologies Ltd
SHE:002808
|
China | CN¥403.39 Million |
|
Flexidynamic Holdings Bhd
KLSE:0231
|
Malaysia | RM55.58 Million |
|
Erria A/S
CO:ERRIA
|
Denmark | Dkr68.77 Million |
|
Green Earth Group N.V.
AS:HWK
|
USA | €141.00K |
|
COSCIENS Biopharma Inc.
NASDAQ:CSCI
|
USA | $20.46 Million |
|
YLI Holdings Bhd
KLSE:7014
|
Malaysia | RM37.90 Million |
|
CS Corporation
KQ:065770
|
Korea | ₩2.63 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Chemomab Therapeutics Ltd DRC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CMMB current and non-current assets.
Liquidity & Leverage Metrics
Chemomab Therapeutics Ltd DRC Total Liabilities Ratios Explained
Chemomab Therapeutics Ltd DRC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chemomab Therapeutics Ltd DRC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chemomab Therapeutics Ltd DRC (2012–2025)
The table below shows the annual total liabilities of Chemomab Therapeutics Ltd DRC from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.48 Million | -56.87% |
| 2024-12-31 | $3.43 Million | -33.51% |
| 2023-12-31 | $5.15 Million | -24.65% |
| 2022-12-31 | $6.84 Million | +136.92% |
| 2021-12-31 | $2.89 Million | +72.46% |
| 2020-12-31 | $1.67 Million | -65.46% |
| 2019-12-31 | $4.85 Million | +63.94% |
| 2018-12-31 | $2.96 Million | +9.64% |
| 2017-12-31 | $2.70 Million | +14.41% |
| 2016-12-31 | $2.36 Million | +71.93% |
| 2015-12-31 | $1.37 Million | -77.87% |
| 2012-12-31 | $6.19 Million | -- |
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical tri… Read more